Spevigo - Drug Monograph

Introduction

Spevigo (spesolimab-sbzo) is a first-in-class humanized monoclonal antibody that selectively blocks the interleukin-36 receptor (IL-36R). It is the first and only therapy specifically approved for the treatment of generalized pustular psoriasis (GPP) flares in adults. Its development represents a major therapeutic advance for a rare, potentially life-threatening autoinflammatory skin disease.

Drug Class and Overview

• Class: Interleukin-36 receptor antagonist (monoclonal antibody, IgG1)
• Related agents: No other IL-36 pathway inhibitors are currently FDA-approved; other biologic psoriasis therapies (e.g., TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors) target different cytokine pathways and are not specifically approved for GPP.
• Key distinguishing feature: Spevigo directly blocks the IL-36 signaling axis, which is the central pathogenic driver in GPP, distinguishing it from biologics used for plaque psoriasis.

Mechanism of Action

Spesolimab is a recombinant humanized monoclonal antibody that binds with high affinity to the IL-36 receptor (IL-36R), preventing the binding of the agonistic cytokines IL-36α, IL-36β, and IL-36γ. This blockade inhibits downstream proinflammatory signaling, including NF-κB and MAPK pathway activation, reducing the production of inflammatory cytokines and chemokines. In GPP, loss-of-function mutations in IL36RN (encoding the IL-36 receptor antagonist) lead to unopposed IL-36 signaling; by blocking the receptor itself, spesolimab suppresses the uncontrolled neutrophilic inflammation that drives pustule formation and systemic symptoms.

Indications

• FDA-approved: Treatment of generalized pustular psoriasis (GPP) flares in adults.
• Evidence-based use: Acute flare control in GPP, including reduction of pustules and systemic inflammation; not indicated for plaque psoriasis or other psoriasis subtypes.

Dosage and Administration

• Adult dosing: 900 mg administered as a single intravenous infusion over 90 minutes.
• Route: IV only; no subcutaneous formulation is approved.
• Renal/hepatic adjustment: No formal studies; monoclonal antibodies are not expected to require dose adjustment in renal or hepatic impairment.
• Special populations:
• Pediatric: Safety and efficacy not established in patients under 18 years.
• Geriatric: No specific dose adjustment required; clinical studies included limited numbers of patients ≥65 years.
• Pregnancy: Limited human data; based on animal studies, no evidence of teratogenicity, but IgG antibodies cross the placenta in the third trimester. Use only if clearly needed.
• Lactation: Unknown if secreted in human milk; consider developmental benefits of breastfeeding against maternal need for therapy.

Pharmacokinetics

• Absorption: Not applicable (IV administration).
• Distribution: Primarily confined to the vascular and interstitial compartments; typical for IgG monoclonal antibodies.
• Metabolism: Degraded into small peptides and amino acids via nonspecific catabolic pathways (reticuloendothelial system); not metabolized by CYP450 enzymes.
• Elimination: Clearance via intracellular catabolism; no renal or biliary excretion of intact antibody.
• Half-life: Approximately 27 days (range ~23–31 days in clinical studies).
• Time to peak effect: Clinical response (pustule clearance) typically observed within 1 week of infusion.

Contraindications

• No absolute contraindications are listed in the FDA prescribing information.
• Caution (relative contraindications): Known severe hypersensitivity to spesolimab or any excipients; active, serious infection (initiation should be deferred until infection resolves).

Warnings and Precautions

• Infections: Spevigo may increase the risk of infections. Serious infections, including sepsis, have been reported. Patients with chronic infection or a history of recurrent infection should be treated with caution. If a serious infection develops, discontinue therapy until it resolves.
• Tuberculosis (TB): Evaluate patients for TB infection prior to initiating therapy. Do not administer to patients with active TB; treat latent TB before starting treatment.
• Hypersensitivity reactions: Infusion-related reactions and hypersensitivity (including angioedema, urticaria, and anaphylaxis) may occur. Monitor during and after infusion; discontinue if a severe reaction develops.
• Live vaccines: Do not administer live vaccines during treatment. Complete all age-appropriate vaccinations prior to starting therapy.
• No boxed warning is present in the FDA label.

Drug Interactions

• Live vaccines: Avoid concurrent administration; immune response may be impaired.
• CYP450 substrates: No clinically relevant interactions expected, as monoclonal antibodies do not interact with CYP enzymes.
• Immunosuppressants/biologics: No formal interaction studies; concurrent use with other immunosuppressive agents has not been adequately studied and should be approached cautiously.
• No drug–drug interaction studies have been conducted per the FDA label; monoclonal antibody pharmacokinetics are generally unaffected by small-molecule drugs.

Adverse Effects

Common (≥5% in clinical trials):

• Asthenia and fatigue
• Nausea
• Headache
• Pruritus and prurigo
• Infusion-related reactions (e.g., flushing, dyspnea, hypotension)

Serious/Rare:

• Serious infections (including sepsis)
• Hypersensitivity reactions (anaphylaxis, angioedema)
• Neutropenia (reported in some patients; clinical significance not fully established)

Monitoring Parameters

• Before initiation: Screen for active or latent TB (e.g., tuberculin skin test or IGRA); assess for active infections; complete age-appropriate vaccinations.
• During infusion: Monitor for signs of infusion-related reactions (vital signs, respiratory status, skin changes).
• After infusion: Monitor for signs/symptoms of infection (fever, malaise, localized symptoms) and for hypersensitivity reactions in the days following administration.
• Laboratory: No routine lab monitoring is mandated by the label; consider CBC if infection is suspected.

Patient Education

• Spevigo is given as a single intravenous infusion; you will be monitored during and after the infusion.
• Report any signs of infection (fever, chills, sore throat, cough, painful urination) to your healthcare provider promptly.
• Tell your doctor if you have had tuberculosis, have been exposed to TB, or have a history of recurrent infections.
• Do not receive live vaccines (e.g., measles-mumps-rubella, varicella, nasal flu vaccine) while being treated with Spevigo; discuss vaccination schedules with your doctor.
• If you are pregnant, planning to become pregnant, or breastfeeding, discuss this with your healthcare provider before treatment.
• Seek immediate medical attention if you experience symptoms of an allergic reaction (hives, swelling of the face/lips/tongue, difficulty breathing).

Clinical Pearls

1. Spevigo is the first FDA-approved therapy specifically for GPP flares, filling a major unmet need for a disease previously treated off-label with acitretin, cyclosporine, or methotrexate.
2. The pivotal Effisayil-1 trial demonstrated rapid clearance of pustules, with a significant proportion of patients achieving visible pustule clearance within 1 week of a single 900 mg IV dose.
3. Unlike IL-17 or IL-23 inhibitors used in plaque psoriasis, Spevigo targets the IL-36 pathway, which is uniquely implicated in GPP pathogenesis (including IL36RN mutations).
4. Because it is a monoclonal antibody, no CYP-mediated drug interactions are expected, simplifying co-prescribing in patients on multiple medications.
5. The long half-life (~27 days) means a single dose provides sustained pharmacodynamic effect, but also means that adverse effects (e.g., infection risk) may persist for weeks after administration.
6. Always screen for latent TB before use, and ensure live vaccines are administered prior to (not during) treatment.

References

1. Boehringer Ingelheim. SPEVIGO (spesolimab-sbzo) injection, for intravenous use: Prescribing Information. U.S. Food and Drug Administration. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761244s000lbl.pdf
2. Bachelez H, Choon SE, Marrakchi S, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385(26):2431-2440.
3. Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365(7):620-628.
4. U.S. Food and Drug Administration. FDA approves first treatment for generalized pustular psoriasis flares. FDA News Release. September 1, 2022. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-generalized-pustular-psoriasis-flares
5. Katzung BG, Vanderah TW. Basic and Clinical Pharmacology. 15th ed. McGraw-Hill Education; 2021.
6. Brunton LL, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 13th ed. McGraw-Hill Education; 2018.
7. Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792-1799.
8. World Health Organization. WHO Model List of Essential Medicines. 23rd List. Geneva: World Health Organization; 2023. https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02